Michael Joseph Smith

Professor of Pediatrics

Pediatrics, Infectious Diseases

michael.j.smith@duke.edu

More About This Person

At a Glance

Credentials
1. Education
2. Training & Certifications

Academic Experience
1. Current Appointments & Affiliations
2. Previous Appointments & Affiliations

Expertise
1. Keywords
2. Global Scholarship

Research
1. Selected Grants

Publications
1. Selected Publications

Artistic Works / Events

Teaching

Advising & Mentoring

Recognition

Professional Activities

Selected Grants

CISA 2023 Clinical Contributing Task 1

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

CISA 2023 Clinical Contributing Task 2

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2023 - 2028

Clinical and host microbiome features in the development of acute otitis media

ResearchAdvisor · Awarded by National Institutes of Health · 2023 - 2028

CISA 2024 RSV Infants Nirsevimab Study Task 1 - Lead

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2024 - 2027

CIVICS Component C - Option 9

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2026

Lead Site Optional Task 1: Babies COVID-19 Vaccination

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2025

CIVICS Component C - Option 4

ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2025

A Phase 2, randomized, partially double-blind trail to evaluate the safety, tolerability and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in healthy toddlers 12 through 15 months of age.

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2025

A Phase 2, randomized, double-blind trial to evaluate the safety, tolerability, and immunogenicity of a multivalent pneumococcal conjugate vaccine in healthy infants

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2024 - 2025

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 1

ResearchInvestigator · Awarded by National Institutes of Health · 2022 - 2025

CIVICS Component C - Option 8

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2024

CISA COVID Peds Immunogenicity

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2024

CISA 10-Pediatric COVID-19 Vaccination (Lead)

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2021 - 2024

A Phase 1, Open-Label, Age-Descending, Dose-Finding Study and A Phase 2/3, Placebo-Controlled, Randomized, Double-Blind Study To Evaluate the Safety, Tolerability and Immunogenicity of Respiratory Synctial Virus Perfusion F Subunit Vaccine - RSVpreF

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2023 - 2024

Pfizer C4671026

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2022 - 2024

Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Option 4

ResearchInvestigator · Awarded by National Institutes of Health · 2023 - 2024

A Master Protocol to Investigate the Safety, Tolerability and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Infants and Children

Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2022 - 2023

CISA Consult 2022 Contributing Task 3

Clinical TrialPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023

CISA Consult 2022 Contributing Task 1

ResearchPrincipal Investigator · Awarded by Centers for Disease Control and Prevention · 2022 - 2023

Leveraging National Healthcare Safety Network Antimicrobial Use Option to Inform, Implement and Assess Antibiotic Stewardship Activities

ResearchConsultant · Awarded by Centers for Disease Control and Prevention · 2022 - 2023

CISA RFTP Syncope Prevention Study (Lead) 2020-2022

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022

Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3

ResearchCo Investigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2022

FY21 and FY22 Improving Care Quality for Children 50/50

ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2020 - 2022

Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants

Clinical TrialPrincipal Investigator · Awarded by Sanofi US · 2020 - 2022

The impact of a provider feedback intervention on inappropriate antibiotic prescribing in Kentucky children: An interrupted time series analysis

ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2021 - 2022

Evaluating SARS-CoV2 vaccine effectiveness among health care personnel during early phase vaccination

ResearchInvestigator · Awarded by Centers for Disease Control and Prevention · 2020 - 2021

VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1

ResearchInvestigator · Awarded by National Institutes of Health · 2020 - 2021

Characterizing Health Disparities in the Shift to North Carolina Medicaid Managed Care

ResearchInvestigator · Awarded by Kate B. Reynolds Charitable Trust · 2020 - 2021

VTEU Protocol Implementation Option 1

ResearchCo-Principal Investigator · Awarded by National Institutes of Health · 2019 - 2021

A Phase 1, Open-Label, Multicenter Study to Determine the Pharmacokinetics and Safety of Intravenous Eravacycline in Children with Suspected or Confirmed Bacterial Infection

Clinical TrialPrincipal Investigator · Awarded by Tetraphase Pharmaceuticals, Inc. · 2019 - 2021

A cross-sectional analysis of inappropriate outpatient antibiotic use in children insured by Kentucky Medicaid

ResearchPrincipal Investigator · Awarded by University of Louisville Research Foundation, Inc. · 2020 - 2021

A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T

Clinical TrialPrincipal Investigator · Awarded by Moderna Therapeutics, Inc. · 2020 - 2020